The burden of Progressive Fibrotic Interstitial lung disease across the UK

Thomas Simpson, Shaney L Barratt, Paul Beirne, Nazia Chaudhuri, Anjali Crawshaw, Louise E Crowley, Sophie Fletcher, Michael A Gibbons, Philippa Hallchurch, Laura Horgan, Ieva Jakaityte, Thomas Lewis, Tom McLellan, Katherine J Myall, Ryan Miller, David J F Smith, Stefan Stanel, Muhunthan Thillai, Fiona Thompson, Timothy WallisZhe Wu, Philip L Molyneaux*, Alex G West

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

6 Citations (Scopus)
34 Downloads (Pure)

Abstract

[No abstract]
Original languageEnglish
Article number2100221
Number of pages4
JournalThe European respiratory journal
Volume58
Issue number1
Early online date7 Mar 2021
DOIs
Publication statusPublished - 1 Jul 2021

Bibliographical note

Funding Information:
Conflict of interest: T. Simpson reports non-financial support (educational support/leadership course) from Boehringer Ingelheim, outside the submitted work. S.L. Barratt reports grants, personal fees and non-financial support for meeting attendance from Boehringer Ingelheim, outside the submitted work. P. Beirne reports personal fees for consultancy and non-financial support for meeting attendance from Boehringer Ingelheim Pharmaceuticals, outside the submitted work. N. Chaudhuri reports grants and personal fees for consultancy from Boehringer Ingelheim, personal fees for consultancy from Roche, outside the submitted work. A. Crawshaw has received honoraria from Boehringer Ingelheim for educational meetings (chair/talks) and grants for virtual attendance at international conferences. L.E. Crowley has nothing to disclose. S. Fletcher has nothing to disclose. M.A. Gibbons has served on advisory boards and received support to attend conferences from Roche and Boehringer Ingelheim. P. Hallchurch has nothing to disclose. L. Horgan has nothing to disclose. I. Jakaityte has nothing to disclose. T. Lewis has nothing to disclose. T. McLellan reports unrestricted educational grants from Boehringer Ingelheim, outside the submitted work. K.J. Myall has nothing to disclose. R. Miller has nothing to disclose. D.J.F. Smith has nothing to disclose. S. Stanel has nothing to disclose. M. Thillai has nothing to disclose. F. Thompson has nothing to disclose. T. Wallis has nothing to disclose. Z. Wu has nothing to disclose. P.L. Molyneaux, via his institution, received industry–academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche, outside the submitted work. A.G. West has nothing to disclose.

Funding Information:
Support statement: P.L. Molyneaux is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship.

Fingerprint

Dive into the research topics of 'The burden of Progressive Fibrotic Interstitial lung disease across the UK'. Together they form a unique fingerprint.

Cite this